Use of alkaline phosphatase for preventing or reducing liver disease
The present invention provides a use for alkaline phosphatase for the manufacture of a medicament for the prevention or reduction of toxic LPS influx through a mucosal lining of a mammalian body cavity. A source of alkaline phosphatase is administered for the prophylaxis or treatment of LPS mediated or exacerbated diseases. The invention also provides compositions comprising a source of alkaline phosphatase for the prevention or reduction of (toxic) LPS influx or passage through mucosal layers.
1. A method for preventing or reducing lipopolysaccharide (LPS) toxicity in a subject, comprising administering a composition comprising an alkaline phosphatase (AP) that is suitable for preventing or reducing LPS-induced toxicity in a subject suffering from a liver disease, wherein the AP is delivered to the gastro-intestinal tract of the subject to prevent or reduce said LPS toxicity.
2. The method according to claim 1 , wherein the subject suffers from a disease or condition selected from the group consisting of inflammatory diseases of the gastro-intestinal tract, inflammatory bowel disease, sepsis/septic shock, systemic inflammatory response syndrome (SIRS), meningococcemia, trauma/hemorrhagic shock, burn injuries, cardiovascular surgery/cardiopulmonary bypass, liver surgery/transplant, (necrotizing) enterocolitis, periodontal disease, pneumonia, cystic fibrosis, asthma, coronary heart disease, congestive heart failure, renal disease, hemolytic uremic syndrome, kidney dialysis, autoimmune diseases, cancer, Alzheimer, rheumatoid arthritis, lupus, systemic lupus erythematosus, decreased perfusion of the gastro-intestinal tract and ischemia of the gastro-intestinal tract.
3. A method for preventing or reducing lipopolysaccharide (LPS) toxicity in a subject, comprising administering a composition comprising an alkaline phosphatase (AP) that is suitable for preventing or reducing LPS-induced toxicity in a subject suffering from or at risk of suffering from a liver disease, wherein the AP is delivered to the gastro-intestinal tract of the subject to prevent or reduce said LPS toxicity and wherein the liver disease is caused by cirrhosis, alcohol abuse, or obstructive jaundice.
4. A method for preventing or reducing lipopolysaccharide (LPS) toxicity in a subject, comprising administering a composition comprising an alkaline phosphatase (AP) that is suitable for preventing or reducing LPS-induced toxicity in a subject suffering from or at risk of suffering from a liver disease, wherein the AP is delivered to the gastro-intestinal tract of the subject to prevent or reduce said LPS toxicity and wherein the liver disease is selected from the group consisting of hepatobiliary disease, hepatitis B, hepatitis C, liver cirrhosis, liver fibrosis, bile duct inflammation, and biliary obstruction.
5. The method according to claim 1 , 3 or 4 , wherein the composition is administered orally.
6. The method according to claim 1 , 3 or 4 , wherein the composition is administered topically to the mucosa of the gastro-intestinal tract.
7. The method according to claim 6 , wherein the composition further comprises a pharmaceutically acceptable (i) stabilizer, (ii) activator, (iii) carrier, (iv) permeator, (v) propellant, (vi) disinfectant, (vii) protectant, (viii) diluent, (ix) nutrient or (x) another excipient that promotes AP delivery to said gastro-intestinal tract.
8. The method according to claim 1 , 3 or 4 , wherein the LPS is detoxified, neutralized, or complexed in situ in the gastro-intestinal tract.